Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human anti-Müllerian hormone
- Development stage
- Preclinical
- Lead developer
- Granata Bio
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
Recombinant human anti-Müllerian hormone (rhAMH) is a protein-based therapeutic that mimics the action of the endogenous AMH, a member of the TGF-β superfamily. Developed primarily by researchers at Massachusetts General Hospital and the biotech startup Oviva Therapeutics, rhAMH is being investigated for its ability to regulate ovarian function. Its primary mechanism involves binding to the Anti-Müllerian hormone receptor type 2 (AMHR2), which inhibits the activation of primordial follicles and modulates steroidogenesis. Clinical and preclinical applications include the treatment of polycystic ovary syndrome (PCOS), preservation of the ovarian reserve during chemotherapy, and use as a non-steroidal contraceptive by inducing ovulatory quiescence. Recent research also indicates that rhAMH exposure can influence the transcriptomic profile of pre-implantation embryos, specifically affecting genes involved in hCG production and estrogen synthesis.
- Other names
- rhAMHrecombinant human AMHanti-Müllerian hormone
02
Targets
AMHR2 (Anti-Müllerian hormone receptor type 2)
Beyond the preview
Go deeper on recombinant human anti-Müllerian hormone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human anti-Müllerian hormone.